PRAME peptide (425-433)

PRAME peptide (425-433) is a peptide corresponding to amino acids 425-433 of PRAME (preferentially expressed antigen) in melanoma. PRAME peptide (425-433) can be used to stimulate human PRAME-specific CD8+ T cells[1][2].

Product Specifications

CAS Number

[329314-98-9]

UNSPSC

12352209

Target

Others

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N

Molecular Formula

C46H80N12O12

Molecular Weight

993.20

References & Citations

[1]Spel L, et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 2015 Nov 3;6 (34) :35770-81.|[2]Weber JS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011 Sep;34 (7) :556-67.